4 Výsledek
Eight patients, 7 with hidradenitis suppurativa and 1 with chronic recurrent staphylococcal abscess, all of whom failed to respond to antibiotic therapy, conservative therapeutic measures, and surgery, were experimentally placed on Staphage Lysate. Treatment after appropriate skin testing consisted
BACKGROUND
Hidradenitis suppurativa is a chronic inflammatory disease characterized by significant morbidity. Current medical therapies are usually only minimally effective.
OBJECTIVE
To assess the efficacy and safety of infliximab monotherapy for the treatment of severe extensive refractory forms
An inappropriate immunologic response has been suggested to play a role in the pathogenesis of hidradenitis suppurativa (HS). Adalimumab was the first TNF-α inhibitor approved for moderate to severe HS. We report on a case of HS (Hurley stage 2) in a 39-year-old man, who had received fusidic acid
BACKGROUND
Effective anti-inflammatory treatments for hidradenitis suppurativa (HS) are limited.
OBJECTIVE
To evaluate the efficacy and short-term safety of apremilast in patients with moderate HS.
METHODS
A total of 20 patients with moderate HS were randomized in a 3:1 ratio to receive blinded